(NASDAQ: UPB) Upstream Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.03%.
Upstream Bio's earnings in 2026 is -$143,443,000.On average, 8 Wall Street analysts forecast UPB's earnings for 2026 to be -$172,865,086, with the lowest UPB earnings forecast at -$205,859,923, and the highest UPB earnings forecast at -$147,423,742. On average, 6 Wall Street analysts forecast UPB's earnings for 2027 to be -$199,188,033, with the lowest UPB earnings forecast at -$284,257,355, and the highest UPB earnings forecast at -$135,424,135.
In 2028, UPB is forecast to generate -$285,634,181 in earnings, with the lowest earnings forecast at -$466,118,064 and the highest earnings forecast at -$142,281,053.